文献速递心力衰竭与心肌病

FOXO3A 作为免疫反应调节因子在人类病毒阴性炎症性心肌病中的作用

FOXO3A acts as immune response modulator in human virus-negative inflammatory cardiomyopathy.
PubMed 文献 · Heart · 2023-05-15

本研究探讨 FOXO3A 功能获得性单核苷酸多态性 rs12212067 对炎症性扩张型心肌病(DCMi)患者炎症与结局的影响。在 221 例病毒阴性 DCMi 患者中,携带 SNP 者 6 个月后 LVEF 与临床症状改善更显著,且伴随心脏炎症细胞标志物下降,提示 FOXO3A 可能调节心脏免疫反应、减轻病原体阴性 DCMi 的心肌炎症与损伤。

要点

  • SNP rs12212067 分布与病毒感染或炎症易感性无关。
  • 病毒阴性 DCMi 中,SNP 携带者 6 个月 LVEF 改善优于非携带者。
  • SNP 携带者心脏炎症标志物下降更显著,ΔMac-1+ 等可预测心功能改善。

核心结论

  • FOXO3A 可能作为心脏免疫反应调节因子,减轻病原体阴性 DCMi 的心脏炎症与损伤。

研究设计与样本

  • 研究比较病毒阳性、病毒阴性 DCMi 患者及无心肌病理对照者的 SNP 分布。
  • 在 221 例病毒阴性 DCMi 伴心脏炎症和 LVEF 降低的患者中,按 SNP 携带状态比较基线与结局数据。

主要发现

  • SNP rs12212067 在病毒阳性(n=22,19.3%)、病毒阴性(n=45,20.4%)与对照(n=18,23.4%)间分布无差异(p=0.199)。
  • 病毒阴性 DCMi 组基线 LVEF 35.5%(95%CI 33.5–37.4),LVEDD 59.8 mm(95%CI 58.5–61.2)。
  • SNP 与非 SNP 携带者基线 LVEF 分别为 39.2%(95%CI 34.3–44.0)与 34.5%(95%CI 32.4–36.5),p=0.083;LVEDD 分别为 58.9 mm(95%CI 56.3–61.5)与 60.1 mm(95%CI 58.6–61.6),p=0.702。
  • 基线炎症浸润数量在两组间无差异。
  • 6 个月后 SNP 携带者 LVEF 改善至 50.9%(95%CI 45.4–56.3),非携带者为 41.7%(95%CI 39.2–44.2),p≤0.01。

关键数值与推荐

  • 病毒阴性 DCMi 患者 LVEF 降低(均值 35.5%,95%CI 33.5–37.4)且 LVEDD 增大(均值 59.8 mm,95%CI 58.5–61.2)。
  • SNP rs12212067 携带状态与 6 个月 LVEF 改善相关(50.9% vs 41.7%,p≤0.01)。

临床怎么用

  • 对病毒阴性炎症性 DCMi 患者,可关注 FOXO3A SNP rs12212067 携带状态以评估炎症调节与心功能恢复潜力。
  • 监测心脏炎症标志物(如 CD45RO+、Mac-1+、LFA-1+、CD54+)变化可能有助于判断 SNP 携带者的治疗反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Inflammatory cardiomyopathy is characterised by inflammatory infiltrates leading to cardiac injury, left ventricular (LV) dilatation and reduced LV ejection fraction (LVEF). Several viral pathogens and autoimmune phenomena may cause cardiac inflammation.The effects of the gain of function FOXO3A single-nucleotide polymorphism (SNP) rs12212067 on inflammation and outcome were studied in a cohort of patients with inflammatory dilated cardiomyopathy (DCMi) in relation to cardiac viral presence. METHODS: Distribution of the SNP was determined in virus-positive and virus-negative DCMi patients and in control subjects without myocardial pathology. Baseline and outcome data were compared in 221 virus-negative patients with detection of cardiac inflammation and reduced LVEF according to their carrier status of the SNP. RESULTS: Distribution of SNP rs12212067 did not differ between virus-positive (n=22, 19.3%), virus-negative (n=45, 20.4 %) and control patients (n=18, 23.4 %), indicating the absence of susceptibility for viral infection or inflammation per se (p=0.199). Patients in the virus-negative DCMi group were characterised by reduced LVEF 35.5% (95% CI) 33.5 to 37.4) and increased LVEDD (LV end-diastolic diameter) 59.8 mm (95% CI 58.5 to 61.2). Within the group, SNP and non-SNP carriers had similarly impaired LVEF 39.2% (95% CI 34.3% to 44.0%) vs 34.5% (95% CI 32.4 to 36.5), p=0.083, and increased LVEDD 58.9 mm (95% CI 56.3 to 61.5) vs 60.1 mm (95% CI 58.6 to 61.6), p=0.702, respectively. The number of inflammatory infiltrates was not different in both SNP groups at baseline. Outcome after 6 months showed a significant improvement in LVEF and clinical symptoms in SNP rs12212067 carriers 50.9% (95% CI 45.4 to 56.3) versus non-SNP carriers 41.7% (95% CI 39.2 to 44.2), p≤0.01. The improvement in clinical symptoms and LVEF was associated with a significant reduction in cardiac inflammation (ΔCD45RO+ p≤0.05; ΔMac-1+ p≤0.05; ΔLFA-1+ p≤0.01; ΔCD54+ p≤0.01) in the SNP cohort versus non-SNP cohort, respectively. Subgroup analyses identified ΔMac-1+, ΔLFA-1+, ΔCD3+ and Δperforin+ as predictors for improvement in cardiac function in SNP-positive patients. CONCLUSION: FOXO3A might act as modulator of the cardiac immune response, diminishing cardiac inflammation and injury in pathogen-negative DCMi.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Makrutzki-Zlotek K, Escher F, Karadeniz Z, et al. FOXO3A acts as immune response modulator in human virus-negative inflammatory cardiomyopathy. Heart. 2023. PMID: 36702542. doi:10.1136/heartjnl-2022-321732

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。